The Malaysian Reserve

Aucta Pharmaceuticals, Inc. (“Aucta Pharmaceuticals”) prepares for the launch of PYQUVI™ (deflazacort) oral suspension, the first of a new branded-generic rare disease ...

ZELVYSIA is anticipated to launch in March 2026, shortly following the introduction of PYQUVI. Together, these launches represent a significant step forward in Aucta Pharmaceuticals’ branded generic ...
Le Lézard

Aucta Pharmaceuticals, Inc. ("Aucta Pharmaceuticals") prepares for the launch of PYQUVItm (deflazacort) oral suspension, the first of a new branded-generic rare disease product ...

Aucta Pharmaceuticals is pleased to announce the late January launch of PYQUVI oral suspension 22.75 mg/mL.  PYQUVI, a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) ...
Clinical Advisor

The Clinical Challenge of Diagnosing Hypertrophic Cardiomyopathy at Midwest Medical Center

HCM is a genetic disease, usually caused by mutations in sarcomere proteins such as myosin, actin, tropomyosin, and myosin-binding protein C.
Le Lézard

Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK ...

Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced preliminary, unaudited fourth quarter and full ...